Takeda Pharm Stock Price, News & Analysis

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced that the FDA granted Breakthrough Therapy Designation to TAK-994, an oral orexin agonist in Phase 2 trials for treating excessive daytime sleepiness (EDS) in narcolepsy type 1 patients. This designation aims to expedite development for serious conditions and indicates promising preliminary clinical data suggesting improved wakefulness metrics. TAK-994 represents a significant step in addressing orexin deficiency in NT1 and is part of Takeda's innovative neuroscience research.

Takeda has announced the results of a phase 3 trial for recombinant von Willebrand factor (rVWF) prophylaxis, presented at the ISTH Virtual Congress 2021. The study involved 23 patients with severe von Willebrand disease (VWD) over 12 months. Results indicated a 91.5% reduction in spontaneous, treated annualized bleeding rates (sABRs) compared to historical data from prior on-demand treatments. No new safety risks were identified, bolstering Takeda's commitment to improving patient outcomes in rare bleeding disorders.

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) has filed its Corporate Governance Report with the Tokyo Stock Exchange, as required for TSE listed companies. This report is based on the Corporate Governance Code effective since June 1, 2018, with a revised version due by December 2021. The report can be accessed on Takeda’s website. An English version has also been submitted to the U.S. Securities and Exchange Commission. For more information about Takeda's corporate governance policies and ESG initiatives, refer to their 2021 Annual Integrated Report.

Takeda announced positive results from final analyses of the Phase 3 HELP Study™ Open-label Extension, demonstrating the long-term efficacy and safety of TAKHZYRO® (lanadelumab) for hereditary angioedema (HAE). The study involved 212 patients, revealing an 87.4% average reduction in attack rates, with up to 92.4% reduction during the steady state. The treatment maintained attack-free status for 58.6% of patients after six months. TAKHZYRO was well-tolerated across various demographics, with 54.7% experiencing treatment-related adverse effects. Results presented at the EAACI Congress reflect an important milestone for HAE management.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has filed its Annual Report on Form 20-F for the fiscal year ending March 31, 2021, with the SEC on June 29, 2021. The report is available on Takeda's website. Additionally, Takeda has published its 2021 Annual Integrated Report, accessible online. The company emphasizes its commitment to research and development in various therapeutic areas, including Oncology and Neuroscience, while offering free hard copies of the Annual Report to shareholders upon request.

Takeda has launched the "In Their Shoes" platform in the Middle East, an immersive simulation program aimed at increasing awareness of Inflammatory Bowel Disease (IBD) among healthcare providers. This innovative program allows participants to experience patient challenges through a mobile app and role-playing scenarios. An evaluation by the University of Westminster revealed significant improvements in empathy and understanding towards IBD patients. Since its inception, over 1,900 participants from more than 30 countries have engaged with the program, enhancing support for those affected by IBD.

Takeda Pharmaceutical Company has reported positive results from the Phase 3 TAK-620-303 (SOLSTICE) trial for the investigational drug TAK-620 (maribavir), aimed at treating cytomegalovirus (CMV) infections in solid organ transplant (SOT) recipients. Achieving a 55.6% clearance rate at Study Week 8 for those treated with maribavir, compared to 26.1% for conventional therapies. Notably, lung transplant recipients showed a 47.5% success rate with maribavir. The trial met its primary endpoint with significantly fewer treatment-related toxicities. Maribavir is designed to offer a safer, more effective alternative for CMV infection treatment.

Takeda announced promising results for its dengue vaccine candidate, TAK-003, showing sustained protection against dengue illness and hospitalization over three years. In the ongoing Phase 3 TIDES trial, involving over 20,000 children and adolescents, TAK-003 demonstrated an overall vaccine efficacy (VE) of 62.0% against confirmed dengue and an impressive 83.6% VE against hospitalized cases. No significant safety risks were identified, reinforcing TAK-003's potential impact in dengue-endemic regions.